The latest price target for Hims & Hers Health (NYSE:HIMS) was reported by Citigroup on January 10, 2025. The analyst firm set a price target for $25.00 expecting HIMS to fall to within 12 months (a possible -10.59% downside). 35 analyst firms have reported ratings in the last year.

The latest analyst rating for Hims & Hers Health (NYSE:HIMS) was provided by Citigroup, and Hims & Hers Health downgraded their sell rating.

The last upgrade for Hims & Hers Health Inc happened on February 9, 2023 when Jefferies raised their price target to $11. Jefferies previously had a hold for Hims & Hers Health Inc.

The last downgrade for Hims & Hers Health Inc happened on January 10, 2025 when Citigroup changed their price target from $24 to $25 for Hims & Hers Health Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Hims & Hers Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Hims & Hers Health was filed on January 10, 2025 so you should expect the next rating to be made available sometime around January 10, 2026.

While ratings are subjective and will change, the latest Hims & Hers Health (HIMS) rating was a downgraded with a price target of $24.00 to $25.00. The current price Hims & Hers Health (HIMS) is trading at is $27.96, which is out of the analyst’s predicted range.